Lima Fabricio O, Mont'Alverne Francisco José Arruda, Bandeira Diego, Nogueira Raul G
Post-Graduate Program in Medical Sciences, Universidade de Fortaleza, Fortaleza, Brazil.
Neurology Service, Hospital Geral de Fortaleza, Fortaleza, Brazil.
Front Neurol. 2019 Sep 13;10:955. doi: 10.3389/fneur.2019.00955. eCollection 2019.
The social and financial burden of stroke is remarkable. Stroke is a leading cause of death and long-term disability worldwide. For several years, intravenous recombinant tissue plasminogen activator (IV rt-PA) remained as the only proven therapy for acute ischemic stroke. However, its benefit is hampered by a narrow therapeutic window and limited efficacy for large vessel occlusion (LVO) strokes. Recent trials of endovascular therapy (EVT) for LVO strokes have demonstrated improved patient outcomes when compared to treatment with medical treatment alone (with or without IV rt-PA). Thus, EVT has become a critical component of stroke care. As in IV rt-PA, time to treatment is a crucial factor with high impact on outcomes. Unlike IV rt-PA, EVT is only available at a limited number of centers. Considering the time sensitive benefit of reperfusion therapies of acute ischemic stroke, costs and logistics associated, it is recommended that regional systems of acute stroke care should be developed. These should include rapid identification of suspected stroke, centers that provide initial emergency care, including administration of IV rt-PA, and centers capable of performing endovascular stroke treatment with comprehensive periprocedural care to which rapid transport can be arranged when appropriate. In the pre-hospital setting, the development of scales easier and quicker to perform than the NIHSS yet with a maintained accuracy for detecting LVO strokes is of paramount importance. Several scales have been developed. On the other hand, the decision whether to transport to a primary stroke center (PSC) or to a comprehensive stroke center (CSC) is complex and far beyond the simple diagnosis of a LVO. Ongoing studies will provide important answers to the best transfer strategy for acute stroke patients. At the same time, the development of new technologies to aid in real time the decision-making process will simplify the logistics of regional systems for acute stroke care and, likely improve patients' outcomes through tailored selection of the most appropriate recanalization strategy and destination center.
中风的社会和经济负担十分显著。中风是全球范围内导致死亡和长期残疾的主要原因。多年来,静脉注射重组组织型纤溶酶原激活剂(IV rt-PA)一直是急性缺血性中风唯一经证实有效的治疗方法。然而,其疗效受到治疗窗狭窄以及对大血管闭塞(LVO)性中风疗效有限的限制。最近针对LVO性中风的血管内治疗(EVT)试验表明,与单纯药物治疗(使用或不使用IV rt-PA)相比,患者预后有所改善。因此,EVT已成为中风治疗的关键组成部分。与IV rt-PA一样,治疗时间是对预后有重大影响的关键因素。与IV rt-PA不同的是,EVT仅在少数中心可用。考虑到急性缺血性中风再灌注治疗的时间敏感性益处、相关成本和后勤保障,建议应建立区域急性中风护理系统。这些系统应包括快速识别疑似中风患者、提供初始急救护理(包括静脉注射IV rt-PA)的中心,以及能够进行血管内中风治疗并提供全面围手术期护理的中心,在适当情况下可安排快速转运至这些中心。在院前环境中,开发比美国国立卫生研究院卒中量表(NIHSS)更简便快捷且在检测LVO性中风时仍能保持准确性的量表至关重要。已经开发了几种量表。另一方面,决定将患者转运至初级中风中心(PSC)还是综合中风中心(CSC)是复杂的,远不止简单诊断LVO这么简单。正在进行的研究将为急性中风患者的最佳转运策略提供重要答案。与此同时,开发有助于实时辅助决策过程的新技术将简化区域急性中风护理系统的后勤保障,并可能通过量身定制选择最合适的再通策略和目的地中心来改善患者预后。